Ivosidenib for IDH1-Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real-World Study.

Liver Int · 2025 · PMC12379572 · PMID 40856270

Europe PMC DOI

hedged sentence

0.2500

closest p · 5.0× alpha

0.2500

boldest claim

The sentences

did not reach statistical significancep = 0.25not close (p > 0.1)

Ivosidenib showed a tendency toward higher PR, SD and DCR, which did not reach statistical significance ( p = 0.25, p = 0.27 p = 0.15, respectively) (Figure S4 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.